Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25131301 | 0.85 | CHRM2 (0.35) | HSD11B1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14885141 | 0.85 | SLC6A9 (0.33) | SLC6A9 | |
| SCHEMBL14885223 | 0.85 | SLC6A9 (0.33) | SLC6A9 | |
| SCHEMBL31009117 | 0.83 | HSD11B1 (0.33) | HSD11B1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL30226481 | 0.83 | HSD11B1 (0.33) | HSD11B1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL31008735 | 0.83 | HSD11B1 (0.33) | HSD11B1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL20793566 | 0.82 | SLC6A9 (0.33) | SLC6A9 | |
| SCHEMBL19992816 | 0.77 | — | — | |
| SCHEMBL21128451 | 0.77 | SLC6A9 (0.31) | SLC6A9 | |
| SCHEMBL19992845 | 0.77 | SLC6A9 (0.33) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| WO-2019046330-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | OPRL1, MGLL, OPRK1 | HSD11B1 718/4885SLC6A9 3538/4885CHRM2 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.